10/31/07

SpineOvations Names Joseph Mussey To Board of Directors

San Diego - October 31, 2007 - SpineOvations, a San Diego-based medical technology company focused on the development of new and innovative products, announced today that it has named Joseph Mussey to its Board of Directors.

Mussey brings to SpineOvations’ Board thirty years of corporate leadership experience, including twenty in orthopedics and spine. Mussey served as President and Chief Operating Officer at Interpore Cross International, where under his leadership the company grew sales from $30 million to $100 million and was successfully acquired by EBI, a subsidiary of Biomet (Nasdaq:BMET).

Prior to his service at Interpore Cross, Mussey served as President and Chief Executive Officer of Cross Medical Products, Inc., diversifying the company into multiple segments, which forced sales growth from $.3 million to $13 million in 1997. A graduate of the United Sates Navy Officer Candidate School, Mussey served in the United States Navy for four years, holds a BS in Industrial Engineering from Cornell University, and an MBA from Harvard University.

Mussey also currently serves as CEO and Chairman of the Board of Directors at US Spine in Boca Raton, FL.

SpineOvations is focused on the development of biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications, including non-surgical connective tissue repair. The company’s technology platform consists of a novel, non-surgical application for identifying and treating spinal disc tears or fissures to seal and stabilize the structural integrity of the spinal disc.

SpineOvation’s new treatment concept integrates the use of discography with the administration of the company’s DiscSeal™, an injectable agent for soft tissue engineering, designed to fill and seal the disc defect and provide internal disc stabilization and pain relief for the millions of patients with chronic back pain as a result of internal disc derangement (IDD). This innovative approach offers the potential to provide a cost-effective treatment option for patients with chronic back pain that will delay or possibly prevent the need for more invasive treatments such as surgery for spinal fusion or disc replacement.

“Joe is an elite executive in the Spine industry and we are extremely proud to have him on our Board,” said Neville Alleyne M.D., SpineOvations Chairman of the Board. “The depth and breadth of Joe's experience in spine is sure to be a great asset to our company. We certainly look to his leadership on the board as we move forward into the rapidly evolving spine device marketplace and build a successful future for SpineOvations."

“Joe’s track record speaks for itself,” added SpineOvations’ CEO, M. Ross Simmonds. “It says a great deal that he believes in our technology enough to join our Board. His contributions will be very valuable.”

# # #

SpineOvations is a San Diego-based, privately held medical device company focused on the development of novel, biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications including non-surgical connective tissue repair. The company’s technology platform consists of a novel non-surgical application for identifying and treating spinal discs that have tears or fissures in order to seal the defect and improve structural integrity.

SpineOvation’s DiscSeal™ is a percutaneous injection treatment for patients with Internal Disc Derangement (IDD) and suffering from chronic, discogenic lower back pain. DiscSeal is designed to be an early-stage treatment for those patients who have failed conservative care and who are not yet candidates for the invasive surgical treatment options of total disc replacement or spinal fusion, the largest segment of the spine market. For more information, visit : http://www.spineovations.com

CONTACT: Paul Williams of MediaLine Communications for SpineOvations, 949/916-6880; medialine2@aol.com